Antigens
- Abnormalities in precursor B-cell ALL, 183
- Allogeneic transplantation (single), 288–290
- Cross-lineage expression in ALL, 174–176
- Quantitative polymerase chain reaction (PCR) of, 190–192
- Antigens and biphenotypicity, 204–206
- Antithymulin globulin (ASG), 275–276, 285–286
- Antinuclear antigens, multiplex bead array assays (MBAs) and, 112
- Antiplatelet antibody, 310–311
- Aspergillus
- Blood lymphocyte subset enumeration, process/assay quality control (QC) and, 88–89
- Autoimmune antibodies, multiplex bead array assays (MBAs)
- Autoimmune disorders, multiplex bead array assays
- Automated systems
- B cells
- B cell malignancies
- B cell markers, primary immunodeficiency disease and, 229–230
- B-cell subsets
- B lymphocytes
- See also Mature B cell malignancies
- Bombay blood group, leukocyte glucose-6-phosphate dehydrogenase deficiency and, 251
- Boolean gating strategy, 325
- Blood lymphocyte subset enumeration process/assay quality control (QC) and, 88–89
- Breast cancer
- DNA content of solid tumors
- Bronchoalveolar lavage (BAL) specimens, RBC/PMS/platelet assays and, 305–306
- Budgeting, and implementation of flow cytometry service, 102
- Cardiopulmonary bypass, platelet function abnormalities and, 311
- Cardiovascular disease, platelet function abnormalities and, 311–312
- Chromosome analysis
- Chronic myeloid leukemia, 177–178
- Chronic lymphocytic leukemia, B-cell differentiation and, 48–49
- Chronic myeloproliferative disorders (MPD)
- See Myeloproliferative disorders (MPD)
- Clinical flow cytometry
- Clinical and Laboratory Standards Institute, 102
- Clinical Flow Cytometric Analysis of Neoplastic hematolymphoid Cells Approved Guideline, 85
- Clinical flow cytometry
- Clinical laboratory medicine
- Cytometry
- Flow cytometry
- Flow cytometric analysis of lymphocytes
- Flow cytometric analysis of hematolymphoid cells
- Flow cytometric analysis of neoplastic hematolymphoid cells
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
- Flow cytometry
Cluster designation (CD)
CLSI (Clinical Laboratory Standards Institute), 74
Clinical Laboratories Improvement Amendment (CLIA), 92–93
Compentency assessment, QA and, 92–93
Compensation
Common variable immune deficiency (CVID), 227
College of American Pathologists (CAP), 30, 75–76, 280, 289
Coefficient of variation (CV), 79, 95
CMS (US Centers for Medicare and Medicaid Services), 74
Colinear, 95
College of American Pathologists (CAP), 30, 75–76, 280, 289
Confirmation acute lymphoblastic leukemia antigen (CALLA), 9
B-cell differentiation and, 46, 49
Common variable immune deficiency (CVID), 227
Compensation
Clinical flow cytometry and, 24–25
Definition, 95
QC and, 86–87
Compeptency assessment, QA and, 92–93
Corrective and preventative action (CAPA), as component of quality assurance (QA), 73
Coulter Epics, 326–327
Counts, hematolymphoid neoplasia analysis and, 124
Cross-lineage expression, 204–207. See also Acute myeloid leukemia (AML)
Crossmatching, allogeneic transplantation and, 276–280
Cytokine measurement, multiplex bead array assays (MBAA) and, 112
Current Protocols in Cytometry (CPC), 325–326
CVID, memory B cells in, 227, 230
Cystic fibrosis (CFTR), multiplex bead array assays (MBAA) and, 112
CytoConnect, 66
Cytokines
...and antigen changes in hematopoietic cell differentiation, 40
...multiplex bead array assays (MBAA) measurement, 111
reproducibility, 111
PBSC harvesting and, 321
Cytologic specimens
DNA content of solid tumors sensitivity/speciﬁcity, 348–349
Cytometer. See Flow cytometer
Cytopenias, ALL diagnosis and, 180–181
Cytosoft software, 58
Cytotoxicity evaluation allogeneic transplantation and, 282
compared with MBAA, 112
Cytotoxicity negative-adsorption positive (CYNAP), 275–276
Dako CD34 Count Kit, 328
DakoCytomation, 56
Data acquisition software, 55–57
variables to consider, 77
Data analysis lymphoma analysis and, 131–132
software applications and, 57–59, 61–66
Data Innovations Inc., 66
Defects per million (DPMO), 93–94
Delta-beta thalassemia, flow cytometry and, 11
Dendritic cell generation, hematopoietic cell differentiation and, 42
Density gradient centrifugation, hematolymphoid neoplasia analysis and, 120
Density gradient preparation of leukocytes, 29
Dichroic mirrors, 20
Difference plot, 78–79
Diffuse large B-cell malignancies, 140
DiGeorge syndrome, 227
Diphtheria, multiplex bead array assays (MBAA) and, 111
Disposals, and implementation of flow cytometry service, 102
DNA content automated analysis and, 66
clinical flow cytometry and, 29–30
flow cytometry and, 10–11
fluorochromes and, 27
DNA content of solid tumors diminishing impact of flow cytometry, 345–346
gestational trophoblastic disease
...new immunohistochemical stains, 349
obstacles in breast cancer standardization/new molecular technologies, 346–347
...obstacles in cytologic specimens sensitivity/speciﬁcity, 348–349
obstacles in prostate cancer tumor cell heterogeneity, 348
DNA Cytometry Consensus Conference, 348
Documentation, validation protocol and, 82
Dual platform approach, primary immunodeﬁciency disease and, 217
Dual platform approach to clinical assays, 28
Dysplasias. See also Fluorochromes
propidium iodide, 27
variables to consider, 77
Dyserythropoiesis, adult fetal hemoglobin (HbF) and, 296–297
Economics of health care. See also Business aspects of flow cytometry and future of clinical flow cytometry, 31–32
marketing and, 103
overhead/indirect costs of implementation, 102
personnel/labor/productivity and, 102
test pricing, 102–103
Electronic gating. See Gating
Electronics/computer systems of flow cytometer, 20–21
ELISAs, multiplex bead array assays (MBAAs) and, 108, 111–114
Embryonic stem cells, graft assessment using flow cytometry, 121
Enzyme histochemistry, Thy lymphocytes and, 5
Eosinophils, hematopoietic cell differentiation and, 40–41
Epstein-Barr virus, multiplex bead array assays (MBAAs) and, 111
Erythrocytes
hematopoietic cell differentiation and, 44
monoclonal surface marker assays and, 4
erythroblastic activity evaluation, RBC/PMS/platelet assays and, 299–301
Escheria coli, 255
Ethylene diaminetetraacetic acid (EDTA), hematolymphoid neoplasia analysis and, 119–120
European Working Group on Clinical Cell Analysis (EWGCCA), 326, 329
Excisional biopsy for liquid sample, hematolymphoid neoplasia analysis and, 120–121
Expo32 CXP/RXP software, 56
Extensible Markup Language (XML), 57
Facilities, and implementation of flow cytometry service, 101
FACSCount, 264–266
FACSDiva software, 56
Fc receptor assays, T/B lymphocytes and, 5
F-cell detection/fetomaternal hemorrhage (FMH), 111
Fetomaternal hemorrhage, flow cytometry and, 11
Ficoll preparation, hematolymphoid neoplasia analysis and, 120
Final Rule and Laboratory Accreditation Program, 75–76
Fine-needle aspiration (FNA) for liquid sample, 20–21
Fluorescence/fluorochromes and, 23–24
DNA analysis and, 29–30
design/operation
organisms, 16–17
optics, 18–20
quality control and, 28
Flow cytometric crossmatch (FCXM), 276–280
Flow cytometric PRA (FC-PRA), 281–284
Flow cytometric PRA (FC-PRA) (microparticle), 284–291
Flow cytometry
absolute cell counts using, 28
anaplastic large cell lymphoma (ALCL)
case history, 138
cell sorting and, 22
cellular analysis concepts and, 16
clinical vs research, 21–22
compensation and, 24–25
design/operation
electronics/computer systems, 20–21
fluorochromes and, 18–20
diagnostic laboratory applications for, 10–12
DNA analysis and, 29–30
fluorescence/fluorochromes and, 23–24
future of, 31–32
gating and, 26
 hairy cell leukemia variant
case history, 165
hepatosplenic γδ T-cell lymphoma
case history, 162
image cytometry and, 22–23
limitations of, 30–31
mature T-cell malignancies
case history, 160
quality control and, 28–29, 31
quantitative flow cytometry and, 25–26
safety considerations and, 30
sample preparation considerations for, 26–28
use in clinical laboratory of, 15–16
volumetric capillary cytometry and, 23
Flow cytometry reimbursement, 103–104
FlowJo, 58, 64–65
FlowMax software, 56
Flow-PRA, for detection of anti-HLA antibodies, 110, 114
Fluidics of flow cytometer, 17–18
Fluorescein isothiocyanate (FITC), 24, 323
Fluorescein-conjugated antibodies, dead T/B lymphocytes and, 3–4
Gating
acut myeloid leukemia (AML) and, 171
clinical flow cytometry and, 23–24
FCXM and, 279–280
FCXM and, 279–280
gating and, 26
multiple bead array assays (MBAAs) and, 107–108
Fluorescent in situ hybridization (FISH), 347
Fluorochromes
CD34+ measurement with flow cytometry, 324–325
clinical flow cytometry and, 23–24
primary immunodeficiency disease and, 216
Food and Drug Administration (FDA)
FDA-approved (IVD) assay, 75
and in-vitro diagnostics use of new assays, 75
Frequency distribution histograms, 59–61, 63
Gated vs whole specimen multicolor, hematolymphoid neoplasia analysis and, 124–126
Gating
for AML/ALL/MDS/MPD, 168–169
CD34+ measurement by multiparameter Boolean, 325
case history , 158
CD45 in hematopoietic cell differentiation, 38
case history, 160
clinical flow cytometry and, 26
data analysis and, 61–63
FACS software, 278
HIV/AIDS and, 261–266
Gene rearrangements and ALL, 179–180
Genetic testing. See also Primary immunodeficiency disease
multiplex bead array assays (MBAAs) and, 112
German Reference Protocol, 326–327
Gestational trophoblastic disease
DNA content of solid tumors and new immunohistochemical stains, 349
Giardia lamblia, 219
Glycosyl phosphodiyl inositol (GPI), 298
Good manufacturing practices (GMP), 95
Good, Robert, 321
GPIIIb/IIIa site marker of platelets, 311
Graft adequacy/quality, 322–323, 335
Granulocyte colony-stimulating factor (G-CSF), 341
Granulocytes
hematopoietic cell differentiation and, 36, 39–41
monoclonal surface marker assays and, 4
Growth of cells, DNA analysis and, 29–30
Guava EasyCyte system, 56
flow cytometers of, 18
Guava Technologies EZCD4 (CD4 T-lymphocyte testing), 267
Guidelines. See Regulations/guidelines/references
Haemophilus influenzae, 219
Haplo-identical transplant, 322
Health Information Portability and Accountability Act (HIPAA), 59
Hematogones.
Maturing B-cell precursor hyperplasia vs precursor B-cell
immunophenotypic features, 184
maturation spectrum of, 181–182
quantitative maturation analysis/stages of, 183
Hematology analyzers, 23

INDEX
Hematolymphoid neoplasia analysis
  analytic concepts
  anchor markers, 123–124
  counts, 124
  gated vs whole specimen multicolor, 124–126
  multicolor analysis, 123
  single gate vs multiple gates, 124
postanalytic concepts
  interpretation, 124
  reporting content, 125, 127
  reporting turnaround time, 127
preanalytic concepts
  clinical/morphologic trage, 121–122
  liquid sample collection/transportation, 119–120
  panel selection considerations, 123
  sample type, 122–123
  solid tissue sample collection/transportation, 120–121
Hematopoietic cell differentiation. See also Paroxysmal nocturnal hemoglobinuria (PNH)
  CD designation nomenclature
  noxurnal hemoglobinuria (PNH)
  and, 225–228
  multiplex bead array assays (MBAAs) and, 111
  RBC/PMS/platelet assays and, 301
  leukocyte glucose-6-phosphate dehydrogenase deficiency and, 224–225
  paroxysmal nocturnal hemoglobinuria (PNH) and, 224
  quality assurance (QA) of CD34+ enumeration, 333–334
  rare event detection, 324
  recent developments of aldehyde dehydrogenase (ALDH), 335
  recent developments of CD33, 335
  single-platform CD34+ cell enumeration benefits, 329–333
  single-platform ISHAGE protocol using TruCOUNT tubes, 328–329
  single-platform ISHAGE protocol with viability assessment, 325–327
  definitions, 321
  graft assessment using flow cytometry, 323
  historical background, 321
  stem cell collection and bone marrow harvesting, 322
Hemoglobinopathies
  adult fetal hemoglobin (HbF) and, 296–297
  multiplex bead array assays (MBAAs) and, 112
  paroxysmal nocturnal hemoglobinuria (PNH) and, 298
Hemolytic anemia
  leukocyte glucose-6-phosphate dehydrogenase deficiency and, 255
  RBC/PMS/platelet assays and, 301
Hemophilus influenzae type B, multiplex bead array assays (MBAAs) and, 111
HER2-associated growth promotion, 347
Histological databases, quality control and, 28
HLA typing. See also Allogeneic transplantation
  multiplex bead array assays (MBAAs) and, 109–111
  HLA-DR expression, primary immunodeficiency disease and, 225–228
  Hodgkin lymphoma, autologous transplantation and, 321
Human immudeficiency virus (HIV). See also Acquired immunodeficiency syndrome (AIDS)
  Bill and Melinda Gates Foundation and, 269
  and immunophenotyping for CD4 lymphocytes, 11
  lymphocyte immunophenotyping flow cytometry, 251–267
  future of CD4+ T-lymphocyte testing, 267–269
  history, 250–261
Human leukocyte antigen (HLA), 321
  Hydrogen bonds of antibody-antigen interactions, 6
  Hyper IgE syndrome (HIGM) syndromes
  function-based procedures
    X-linked HIGM syndrome (CD40 ligand measurement), 232, 235–238
    specialized monoclonal antibody panels
      memory B cells in CVID/HIGM syndromes, 230
      primary immunodeficiency disease, 231
  HyperLog, 38
  Hypoxanthine/guanine phosphoribosyl transfers (HGPRT), monoclonal antibody production and, 8
ICD-9 coding/local medical review policies (LMRPS), 104–105
i-Cyt Visionary Biosciences, 66
Identical twin transplants, 322
Image cytometry, 22–23
  clinical flow cytometry and, 22–23
  Immature reticulocyte fraction (IRF), erythropoietic activity evaluation and, 299–301
  Immune deficiency disease. See Primary immunodeficiency disease
  Immunohistochemical stains, 349
  Immunologoical characterization of CD34+ stem cells, 333–334
  Immunophenotyping (routine)
    abnormal HLA-DR expression, 225–228
    absent/low circulating B lymphocytes, 217, 219–220
    CVID/AT/DiGeorge syndrome, 227
    decreased CD4+ T cells, 227
    decreased CD8+ T cells, 227
    definition, 95
    leukemia and, 30
    SCID syndrome (Omenn syndrome), 224–225
    SCID syndrome (overview of findings), 225
    SCID syndrome (Th–, Te–, B–, NK–), 224
    SCID syndrome (Th–, Te–, B+, NK–), 221, 223
    SCID syndrome (Th–, Te–, B+, NK+), 221
    SCID syndrome (Th–, Te–, B-, NK+), 221
    SCID syndrome (Th+, Te+, B–, NK+), 221–222
    SCID syndrome (Th+, Te+, B+, NK–), 224
    SCID syndrome generalities, 219, 221
  Immunophenotyping for CD4 lymphocytes, 11
  Instrument correlation, QC and, 87–88
  Instrumentation, and implementation of flow cytometry service, 100–101
  Integrated Cytometry System, 66
  Integrated signal processing, 20–21
  Integrins, leukocytic phagocytes and, 248–249
  Interassay precision, 79–80
  Intercellular adhesion molecules (ICAMs), leukocytic phagocytes and, 248
  Interferon α and antigen changes in hematopoietic cell differentiation, 40
  primary immunodeficiency disease and, 230–242
  Internal proficiency testing (PT) programs, 91–92
  International Bone Marrow Transplant Registry (IMBTR), 321
  International Classification of Diseases, 9th Revision (ICD-9) codes, 104
  International Society for Laboratory Hematology (ISLH), 308–309
  International Society of Hematotherapy and Graft Engineering (ISHAGE), 323–328, 331–333, 343–344
  International Standards Organization (ISO), 94
  Interional Workshops on Human Leukocyte Differentiation Antigens, 35–36
  Intestinal lung disease, bronchoalveolar lavage (BAL) specimens and, 305–306
INDEX

Leukocytes

Leukocytes. See also Hematolymphoid neoplasia analysis

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte glucose-6-phosphate dehydrogenase deficiency, 255

Leukocytes. See also Hematolymphoid neoplasia analysis

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte glucose-6-phosphate dehydrogenase deficiency, 255

Leukocytes. See also Hematolymphoid neoplasia analysis

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte glucose-6-phosphate dehydrogenase deficiency, 255

Leukocytes. See also Hematolymphoid neoplasia analysis

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte glucose-6-phosphate dehydrogenase deficiency, 255

Leukocytes. See also Hematolymphoid neoplasia analysis

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte glucose-6-phosphate dehydrogenase deficiency, 255

Leukocytes. See also Hematolymphoid neoplasia analysis

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte glucose-6-phosphate dehydrogenase deficiency, 255

Leukocytes. See also Hematolymphoid neoplasia analysis

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte adhesion deficiency (LAD) disorders

Leukocyte glucose-6-phosphate dehydrogenase deficiency, 255

Leukocytes. See also Hematolymphoid neoplasia analysis
Lymphoproliferative disorders, lymphoma analysis and, 148–150
Lysing agents and CD34+ enumeration, 330
Lysoosomal marker of platelets, 311
Macrophages. BAL activation markers for, 306
Major histocompatibility complex (MHC), 322
Malignant cells, marker controls for, 29
MALT/primary effusion lymphomas, mature B-cell malignancies and, 141
Management Sciences Associates, 66, 68
Maternal antibodies. See Adult fetal hemoglobin (HbF)
Mature B-cell malignancies
CD10+, 138
CD11c/cytoplasmic projections, 138–139
CD5+, 137–138
detector, 132–136
diffuse large, 140
immunophenotypic data, 136
MALT/primary effusion lymphomas, 141
plasma cell disorders, 139–140
Mature NK-cell malignancies, 146–147
Mature non-Hodgkin lymphoma, vs slg+ precursor B-cell ALL, 188–189
Mature T-cell malignancies
diagnosis. See also Mature T-cell malignancies subclassifications, 144–145
Maturing B-cell precursor hyperplasia vs precursor B-cell, acute lymphoblastic leukemia (ALL) and, 180–185
Mean equivalent of soluble fluorochrome (MESF), 303
quantitative flow cytometry and, 25
Medicare/Medicaid
Centers for Medicare and Medicaid Services (CMS), 103–104
ICD-9 codes and, 104
Local Medical Review Policies (LMRPs) and, 104
on mark-up of charges, 99–100
Megakaryocytes, hematopoietic cell differentiation and, 43
memory B cells in CVID/HIGM syndromes, primary immunodeficiency disease and, 230
Method validation (MV), 95
Microparticle FC-PRA, 284–291
Microsoft, 67–68
Microsoft Windows, 55
Minimal residual disease (MRD)
in ALL, analysis, 190–192
hematolymphoid neoplasia analysis and, 121
Molecules of equivalent soluble fluorochrome (MESF), 279–280
Monoclonal antibodies, hematopoietic cell differentiation and, 35–36
Monoclonal antibody panels
ataxia telangiectasia, 232
B-cell memory markers, 229–230
chronic granulomatous disease (CGD), 232
HIGM syndromes, 231
memory B cells in CVID/HIGM syndromes, 230
T-cell receptor VB repertoire analysis in CD4/CD8 T-cell subsets, 229
Wiscott-Aldrich syndrome (WAS), 232–234
XLA, BTK, 231
X-linked SCID: γ/CD132, 231
Monoclonal antibody production, 225–228
adult fetal hemoglobin (HbF) and, 296–297
graft adequacy assessment and, 322–323
immunologic reagents and, 7–9
paroxysmal nocturnal hemoglobinuria (PNH) and, 298–299
platelet activation markers of, 311
primary immunodeficiency diseases and, 215–216
RBC/PMS/platelet assays and, 295
trastuzumab and, 347
Monocyte activation changes, RBC/PMS/platelet assays and, 305
Monocytes
BAL activation markers for, 306
hematopoietic cell differentiation and, 41–42
Mononuclear cell count (MNC), as predictor of graft adequacy, 322
Multi-color analysis, hematolymphoid neoplasia analysis and, 123
Multicolor approach to flow cytometry, 31
Multicycle, 58
Multidrug resistance (MDR), hematopoietic cell differentiation and, 37
Multiple myeloma
autologous transplantation and, 321
B-cell differentiation and, 49
Multiple myeloma, case study, 341–342
Multiplex bead array assays (MBAAs)
basic principles/theory, 23, 107–110
clinical applications
autoimmune antibodies, 112
cytokine measurement, 111
genetic testing, 112
HLA typing, 109–111
panel-reactive antibodies, 110
pathogen detection, 111–112
comparison with other techniques, 112–114
sensitivities/reproducibility/stability of, 114–115
Mycobacteria sp., 239, 241
Myeloblasts, hematopoietic cell differentiation and, 39–40
Myelodysplasia, hematolymphoid neoplasia analysis and, 120
Myelodysplastic syndromes (MDS)
averabilities of maturation spectrum and, 203
adult fetal hemoglobin (HbF) and, 296–297
advantages of flow cytometry in diagnosis of, 167
antibody selection/combinations and, 169, 172–173
CD34+ diagnosis of, 200–201
four-color antibody combinations for, 172
gating strategies for, 168–169
Myeloperoxidase deficiency (MPO), 254–255
Myeloproliferative disorders (MPD)
averabilities of maturation spectrum and, 203
advantages of flow cytometry in diagnosis of, 167
antibody selection/combinations and, 169, 172–173
CD34+ diagnosis of, 200–201
four-color antibody combinations for, 172
gating strategies for, 168–169
National Committee for Clinical Laboratory Standards (NCCLS), 102
National Institute of Standards and Technology (NIST), 303
Natural killer (NK) cells
hematopoietic cell differentiation and, 46
SCID syndromes and, 221–226
NCCLS. See CLSI (Clinical Laboratory Standards Institute)
Nisseria meningitidis, multiplex bead array assays (MBAAs) and, 111
Neonatal transfusion therapy
RBC assays and, 296
Neoplasms
flow cytometry
DNA content, 10–11
Neutrophil CD64 quantitation, RBC/PMS/platelet assays and, 301–305
Neutrophil transdifferentiation, hematopoietic cell differentiation and, 40–41
NK-cell malignancies, lymphoma analysis and, 146–147
Nocardia sp., 232
Non-Hodgkin lymphoma
autologous transplantation and, 321
HIV and, 259
vs slg+ precursor B-cell ALL, 188–189
Nonlymphoid cells, hematopoietic cell differentiation and, 37–38
Obstructive sleep apnea syndrome, platelet function abnormalities and, 311
Occupational Safety and Health Administration (OSHA), 30
Off-label assays, 75
Offline analysis software, 57–59
Ovotransferrin syndrome, 224–226
Optics, of flow cytometer, 18–20
Optimization of cell counts, specimen quality/quantity and, 167
Ortho Cytogen Absolute, 264
Overton subtraction method, 63
Oxidative burst assay (CGD), 237–240

INDEX

381
Panel selection/design
hematolymphoid neoplasia analysis and, 123
lymphoma analysis and, 130
Panel-reactive antibodies
multiplex bead array assays (MBAAs) and, 110
Panel-reactive antibody (PRA) analysis
allogeic transplantation
discussion/goals, 280–281
flow cytometric PRA (FC-PRA), 281–284
future clinical applications, 291–292
microparticle FC-PRA, 284–291
PanLeucoGating method, 286–287
Pathogen detection, multiplex bead array assays (MBAAs)
Parasite infections, RBC/PMS/platelet assays and, 301
Paroxysmal nocturnal hemoglobinuria (PNH)
Parasite infections, RBC/PMS/platelet assays and, 298–299
Partec, 56
Partec CyFlow Counter (CD4 T-lymphocyte testing),
Partec, 56
Paroxysmal nocturnal hemoglobinuria (PNH)
Pathogen detection, multiplex bead array assays (MBAAs)
Phagocytes
Peripheral blood stem cells (PBSCs), 321
Peridinin chlorophyll protein (PerCP), 24
Peak-sense-and-hold signal processing, 20–21
Pathogen detection, multiplex bead array assays (MBAAs)
Phagocytes. See Leukocytic phagocytes
Peripheral blood stem cells (PBSCs), 321
Peripheral blood stem cells (PBSCs), 321
Peripheral T-cell lymphoma, vs precursor T-lymphoblastic lymphoma/leukemia, 130
Phagocytes. See Leukocytic phagocytes
Photomultiplier tubes (PMTs), 20
Phytoerythrin (PE), 24, 323
Photomultiplier tubes (PMTs), 20
Phytoerythrin (PE), 24, 323
Plasmodium infections, 301
Platelet associated immunoglobulin, 310–311
Platelet-associated immunoglobulin, 310–311
Platelet-associated immunoglobulin, 310–311
Platelets
antiplatelet antibodies and, 310–311
count of, 307–309
function/kinetics of, 306–307
hematopoietic cell differentiation and, 42–43
method/clinical applications of flow cytometry, 306
platelet function abnormalities, 311–312
reticulated, 309–310
Flow cytometry/dna analysis and, 29
PMN CD64 assay rationale, 302–303
Pneumocystis carinii, 259
PointCare Technologies Aurora (CD4 T-lymphocyte testing), 268
Polyclonal antibody production, immunologic reagents and, 7–8
Polyomavirus-neuronal cells (PMNs)
Population analysis vs single-cell analysis, 16
Portable document format (PDF) files, 69
Positive/negative controls, quality control and, 28–29
Postanalytical process, 95
Preanalytical process, 95
Precision
definition, 95
quality control (QC) and, 73
validation protocol and, 79–80
Precursor B-cell, acute lymphoblastic leukemia (ALL) and, 173–175, 183
Precursor B-cell ALL, MRD analysis in, 191
Precursor T-cell, acute lymphoblastic leukemia (ALL) and, 173–175
Precursor T-lymphoblastic lymphoma/leukemia vs peripheral T-cell lymphoma, 190
vs peripheral T-cell lymphoma, 194
vs thymoma, 185–186
Primary immunodeficiency disease
function-based procedures
ataxia telangiectasia, 241–242
CGD (oxidative burst assay), 237–240
interferon α pathway defects (mycobacterial infections), 239–242
leukocyte adhesion deficiency (LAD) type-1, 235–237
X-linked HIGM syndrome (CD40 ligand measurement), 232, 235–238
routine immunophenotyping, 216–218
abnormal HLA-DR expression, 225–228
absent/low circulating B lymphocytes, 217, 219–220
CVID/A/TcDigeorge syndrome, 227
decreased CD4+ T cells, 227
SCID syndrome (Ommen syndrome), 224–226
SCID syndrome (overview of findings), 225
SCID syndrome (Th–, Tc–, B+, NK–), 224
SCID syndrome (Th–, Tc–, B+, NK+), 221–223
SCID syndrome (Th–, Tc–, B+, NK–), 221
SCID syndrome (Th–, Tc–, B+, NK+), 221–222
SCID syndrome (Th–, Tc–, B+, NK–), 224
SCID syndrome generalities, 225, 229
specialized monoclonal antibody panels
ataxia telangiectasia, 232
B-cell memory markers, 229–230
chronic granulomatous disease (CGD), 232
HIGM syndromes, 231
memory B cells in CVID/HIGM syndromes, 230
T-cell receptor Vβ repertoire analysis in CD4/CD8 T-cell subsets, 225–227, 229
Wiscott-Aldrich syndrome (WAS), 232–234
XLA, 231
X-linked SCID, 231
ProCOUNT assay, 327
Productivity, and implementation of flow cytometry service, 102
Proficiency testing (PT)
as component of quality assurance (QA), 73
definition, 95
Progenitor cell identification
CD34+ measurement with flow cytometry
CD34+ antigens/fluorochrome choice, 324
CD34+/CD3+ enumeration in allogeneic transplants, 333
CD34+ antigens/fluorochrome choice, 325
commercially available assays, 327–328
historical background, 323–324
immunological characterization of CD34+ stem cells, 333–334
isotype controls, 330
lyzing agents, 330–331
quality assurance (QA) of CD34+ enumeration, 331–333
rare event detection, 324
recent developments of aldehyde dehydrogenase (ALDH), 335
recent developments of CD133, 335
single-platform CD34+ cell enumeration benefits, 329–333
single-platform ISHAGE protocol using TruCOUNT tubes, 328–329
single-platform ISHAGE protocol with viability assessment, 323–327
Propidium iodide
as stain, 27
Prostate cancer
DNA content of solid tumors
tumor cell heterogeneity, 348
P-Selectin marker of platelets, 311–312
Pseudomonas aeruginosa, 251
Qualitative assays
definition, 95
QA and, 90
Quality assurance (QA). See also Hematolymphoid neoplasia analysis
assay optimization and, 76–77
CD34+ measurement and, 331–333
competency assessment and, 92–93
components of, 73
definition, 95
initial assay launch preparation, 82
quality assurance (QA) of CD34+ enumeration, 333–334
isotype controls, 330
lyzing agents, 330–331
quality assurance (QA) of CD34+ enumeration, 331–333
rare event detection, 324
recent developments of aldehyde dehydrogenase (ALDH), 335
recent developments of CD133, 335
single-platform CD34+ cell enumeration benefits, 329–333
single-platform ISHAGE protocol using TruCOUNT tubes, 328–329
single-platform ISHAGE protocol with viability assessment, 323–327
Propidium iodide
as stain, 27
Prostate cancer
DNA content of solid tumors
tumor cell heterogeneity, 348
P-Selectin marker of platelets, 311–312
Pseudomonas aeruginosa, 251
Qualitative assays
definition, 95
QA and, 90
Quality assurance (QA). See also Hematolymphoid neoplasia analysis
assay optimization and, 76–77
CD34+ measurement and, 331–333
competency assessment and, 92–93
components of, 73
definition, 95
initial assay launch preparation, 82
new assay validation, 74–76
proficiency testing and, 91–92
qualitative assays, 90
quality audits and, 92
quality control (QC) and
antibody/reagant QC, 88
compensation, 86–87
instrument correlation, 87–88
instrument correlation, 83–86
linearity, 87
quality improvement and, 93
quality audits. See Audits

Quality control (QC)
  antibody/reagent QC and, 88
  compensation and, 86–87
  as component of quality assurance (QA), 73
definition, 96
instrument correlation and, 87–88
instrument QC, 83–86
linearity and, 87
Quality control, clinical flow cytometry and, 28–29
Quality improvement (QI), as component of quality assurance (QA), 73
Quantitative assays
  blood lymphocyte subset enumeration, 88–89
  CD34 stem cell enumeration and, 89–90
definition, 95
Quantitative flow cytometry, clinical flow cytometry and, 25
Quantitative polymerase chain reaction (PCR), and MRD analysis in ALL, 190–192

Rambon-Hasharon syndrome, as LAD, 251

Reagents/disposals, and implementation of flow cytometry service, 102

Red blood cells (RBCs)
  bronchoalveolar lavage (BAL) specimens and, 305–306
  erythropoietic activity evaluation, 299–301
  febrile neutrophilic/F-cell detection in, 296–298
  hemolytic anemia evaluations, 301
  immunohematology and, 295–296
  monocyte activation changes
  sepsis, 305
  neutrophil CD4+ quantitation
  infection/sepsis, 301–305
  parasite infections and, 301
  paroxysmal nocturnal hemoglobinuria and, 298–299
Reference interval, validation protocol and, 81
Reference laboratories, as alternative services, 99–100
Regulations/guidelines/references
  agencies/publications for, 74
  quality assurance (QA) and, 73–74
  Reliability, quality control (QC) and, 73
  Renal dialysis, platelet function abnormalities and, 311
  Reporting content/turnaround time, hematolymphoid neoplasia analysis and, 125, 127
  Reproducibility of results, quality control (QC) and, 73
  Research flow cytometers, vs clinical, 21–22
  Research use only (RUO) assay, 75
  Respiratory viruses, multiplex bead array assays (MBAAs) and, 111
  Reticulated platelets, 309–310
  Reticuloocyte assays, flow cytometry and, 10
  Retrovirus. See Human immunodeficiency virus (HIV)
  Rh immune globulin therapy, RBC assays and, 297
  Robinson-Patman Act, 103
Roederer, Mario, 64–65

Sensitivity
  definition, 96
  DNA content and, 348
  validation protocol and, 80
Sepsis
  monocyte activation changes and, 305
  neutrophil CD4+ quantitation for, 301–305
Serratia marcescens, 232

Severe combined immunodeficiency (SCID), 321
Sheep E-rosette assays, T/B lymphocytes and, 1–3
Sherman Act, 103
Short pass optical filters, 20
Sickle cell disease
  adult fetal hemoglobin (HbF) and, 296–298
  flow cytometry and, 11
  slg+ precursor B-cell ALL vs mature non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and, 188–189
  slgs
  T lymphocytes and, 5
  T/B lymphocytes and, 3–4
  Simian immunodeficiency virus (SIV), 260
  Single gate vs multiple gates, hematolymphoid neoplasia analysis and, 124
  Single platform approach, primary immunodeficiency disease and, 217
  Six Sigma, 93, 96
  Sodium heparin, hematolymphoid neoplasia analysis and, 119–120
Software applications
  automation and, 66–67
  data analysis and, 61–66
  data display and, 59–61
  data-acquisition software, 55–57
  exporting results, 67–69
  offline analysis, 57–59
  variables to consider, 77
Somatic stem cells, 321
Southeastern Organ Procurement Foundation, 280
Specimen handling, quality control and, 28–29
Specimen quality/quantity, and optimization of cell counts, 91
Stability, validation protocol and, 80–81
Stains. See Dyes/stains
  Standard deviation (SD), 79, 96
  Standardization of techniques
  importance of, 31
  variables of, 77
  Staphylococcus aureus, 219
FLOW CYTOMETRY

INDEX

StarStation software, 56
Statistical tools, 78–79
Stem cells. See also Hematopoietic stem cell (HPSCs)
   identification
collection of, 322
hematopoietic cell differentiation and, 36–37
Stem-Kit, 327–328
Stokes’ shift, 23–24
Streptococcus pneumoniae
Streptococcus marcescens
Streptococcus aureus
Stokes’ shift, 23–24
Stem-Kit, 327–328
Super enhanced Dmax subtraction (SED), 63
Surface marker assays
   activated T-cell rosette assay and, 5
   assay problems, 3–4
   C/VCF rosette assays and, 5
   early markers for subpopulations of T/B lymphocytes, 4–5
   enzyme histochemistry
   early markers for subpopulations of T/B lymphocytes, 4–5
   history/evolution of, 1–2
   immunologic reagents
   antibody-antigen interactions, 6–7
   polyclonal/monoclonal antibody production, 7–9
   interlaboratory standardization of CD monoclonal antibodies and/or, 10–12
   pre-flow cell surface assay correlation with monoclonal markers, 9–10
   Suspensions, importance of monodispersed, 17–18
   Syngeneic transplants, 322
   T lymphocytes
   as differ from NK cells, 46
   early markers for subpopulations of, 4–5
   hematopoietic cell differentiation and, 44–46
   immunologic reagents and, 1–3
   maturer T-cell malignancies, 144–146
   and precursors T-lymphoblastic lymphoma/leukemia vs thymoma, 185–188
   precursor T-lymphoblastic lymphoma/leukemia vs thymoma, 185–188
   precursor T-lymphoblastic lymphoma/leukemia vs peripheral T-cell lymphoma
   acute lymphoblastic leukemia (ALL), 190
   and problems with sheep E-rosette assays, 3
   in tissue sections, 6
   Tp lymphocytes, enzyme histochemistry and, 5
   t(1;19), acute lymphoblastic leukemia (ALL) and, 179
   t(12;21), acute lymphoblastic leukemia (ALL) and, 179
   t(9;22), acute lymphoblastic leukemia (ALL) and, 179–180
   Tandem fluorochromes, 24
   T-cell precursors
   acute lymphoblastic leukemia (ALL) and, 175–178
   immunophenotypic aberrancies in, 186–187, 189
   precursor T-lymphoblastic lymphoma/leukemia vs peripheral T-cell lymphoma, 186, 190
   T-cell receptor Vβ repertoire analysis in CD4/CD8 T-cell subsets, primary immunodeficiency disease and, 225–227, 229
   Test pricing, and implementation of flow cytometry service, 102–103
   Test volume, and implementation of flow cytometry service, 100
   Tetanus, multiplex bead array assays (MBAAs) and, 111
   Thalassemias, adult fetal hemoglobin (HbF) and, 296–298
   Thomas, E. Donnall, 321
   Thrombocytopenia
   ALL diagnosis and, 180–181
   RBC/PMS/plaquelet assays and, 295
   Wiscott-Aldrich syndrome (WAS) and, 232
   Thymocytes
   abnormalities in precursor T-cell ALL, 186–187
   maturation in thymoma of, 186–187
   Thymoma, precursor T-lymphoblastic lymphoma/leukemia vs, 185–188
   Tissue, T/B lymphocytes in, 6
   Training
   and implementation of flow cytometry service, 101
   QA and, 92
   Transplantation. See also Allogeneic transplantation
   autologous, 321–322
   erythropoietic activity evaluation and, 300
   HPSC, autologous transplants, 322
   HPSC autologous transplants, 321–322
   Trastuzumab, 347
   Triage, hematolymphoid neoplasia analysis and, 121–122
   Trial Assigning Individualized Options for Treatment (TAILORx), 346
   Typhus infections, 301
   Tumor necrosis factor alpha (TNFα)
   and antigen changes in hematopoietic cell differentiation, 40
   dendritic cell generation and, 42
   Umbilical cord blood transplant, 322
   Undifferentiated acute leukemia, 203–207
   United Kingdom National External Quality Assessment Scheme (UK NEQAS), 263–264, 266
   Unrelated donor transplant, 322
   US-Canadian Consensus Conference, 74
   Validation protocol
   accuracy and, 77–79
   analytic measurement range (AMR)/clinical reportable range (CRR) and, 80
   analytic sensitivity and, 80
   of antibody panel configuration, 81–82
documentation and, 82
   precision and, 79–80
   reference interval and, 81
   sample handling and, 81
   stability and, 80–81
   Validation/verification, 96
   as component of quality assurance (QA), 73
   Van der waals forces antibody-antigen interactions, 6
   Vascular prostheses, platelet function abnormalities and, 311
   Verification, 96
   Viral contamination, 349
   Vascular prostheses, platelet function abnormalities and, 311
   Workshops on Human Leukocyte Differentiation Antigens, 35–36
   World Health Organization (WHO)
   cluster designation (CD) terminology and, 9
   hematolymphoid neoplasias and, 121
   HIV/AIDS numbers, 260
   tumor cell heterogeneity in prostate cancer, 348
   XLA: BTK, primary immunodeficiency disease and, 231
   X-linked HIGM syndrome (CD40 ligand measurement), primary immunodeficiency disease and, 232, 235–238
   X-linked SCID: γCD132, primary immunodeficiency disease and, 231
   xMAP software, 56
   XML. See Extensible Markup Language (XML)